SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 /PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program. As part of the agreement, the pharma leader will enter into a proof-of-concept transfer process for the manufacture of one of its CAR-T cell therapies, using Cellares' automated manufacturing platform, the Cell Shuttle.Read more at prnewswire.com
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.